AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hims & Hers Health Q2 2025 Earnings Preview: Revenue Up 74.9% Y/Y
ByAinvest
Sunday, Aug 3, 2025 5:44 pm ET1min read
Hims & Hers Health (HIMS) is set to announce Q2 2025 earnings on August 4th. The consensus EPS estimate is $0.23, and revenue is expected to reach $552.05M, a 74.9% YoY increase. Over the last year, HIMS' stock has declined 44.4%. The company's performance in Q2 is expected to be strong, with a 74.9% YoY revenue growth.
Hims & Hers Health (HIMS) is scheduled to report its second-quarter 2025 earnings on August 4th after the closing bell. The company has been performing well, with analysts expecting earnings per share (EPS) of $0.23 and revenue to reach $552.05 million, representing a 74.9% year-over-year (YoY) increase [1]. This strong revenue growth is expected to continue the company's upward trajectory despite a 44.4% decline in stock price over the past year.In the first quarter of 2025, HIMS witnessed a significant increase in its subscriber base, driven by higher traffic to its platform and improved customer onboarding experiences [3]. The monthly online revenue per average subscriber also increased, contributing to the company's robust performance.
Looking at the broader context, HIMS has consistently exceeded analysts' revenue expectations, with an average beat of 3.2% over the past two years [1]. This consistent performance has been supported by a strong balance sheet and a diversified revenue stream that includes sexual health, hair loss, dermatology, mental health, and primary care services.
While HIMS' stock has underperformed compared to the S&P 500, the company's growth potential remains high, particularly with its recent acquisition of Zava, a European digital health platform. This acquisition expands HIMS' reach into new markets, such as the U.K., Ireland, France, and Germany, and sets the stage for future growth [2].
Investors should closely monitor HIMS' Q2 2025 earnings report for insights into the company's ability to sustain its growth trajectory. The results will provide a clearer picture of the company's performance in the face of evolving market conditions and regulatory changes.
References:
[1] https://www.tradingview.com/news/stockstory:087ff7e9b094b:0-what-to-expect-from-hims-hers-health-s-hims-q2-earnings/
[2] https://www.nasdaq.com/articles/2-healthcare-stocks-have-doubled-over-last-year-still-have-room-run
[3] https://finance.yahoo.com/news/hims-hers-stock-report-q2-161800798.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet